Macbashi K, Niimi M, Kudoh M, et al. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients[J]. Antimicrob Chemother, 2001, 47(5): 527.
[5]
Marr KA, Lyons CN, Ha K, et al. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans[J]. Anti Agents Chemo, 2001, 45(1): 52.
[6]
Micheli M, Bille J, Schueller C, et al. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drugresistance[J]. Mol Microbiol, 2002, 43(5): 1197-1214.
[7]
Mar MC, Felix GR. Antifungal drug resistance to azole and polyenes[J]. Lancet Infect Dis, 2002, 9(2): 550-563.
[8]
Edlind TD, Henry KW, Metera KA, et al. Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance[J]. Med Mycol, 2001, 39(3): 299.
[9]
Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi[J]. Lancet, 2002, 359 (9312): 1135-1144.
Kohli A, Smriti, Mukhopadhyay K, et al. In vitro low-level resistance to azole in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry[J]. Anti Agents Chemo, 2002, 46(4): 1046.
[12]
Emter R, Heese-Peck A, Kralli A. ERG6 and PDR5 regulate small lipophilic drug accumulation in yeast cells via distinct mechanisms[J]. FEBS Lett, 2009, 521(1-3): 57-61.
[13]
Espinel-Ingroff A. Mechanisms of resistance to antifungalag-ents: Yeasts and filamentous fungi[J]. Rev Iberoam Micol, 2008, 25(2): 101-106.
Rock FL, Mao W, Anya YA, et al. An antifungal agentinhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site[J]. Science, 2007, 316(5832): 1759-1761.
Hope WW, Tabemero L, Denning DW, et al. Molecular mechanisms of primary resistance to flucytosine in Candida albicans[J]. Anti Agents Chemo, 2004, 48: 4377-4386.
Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility[J]. Antimicrob Agents Chemother, 2006, 50(8): 2892-2894.
[25]
Gardiner RE, Souteropoulos P, Park S, et al. Characterization of Aspergillus fumigatus mutants with reduced suscepti-bility to caspofungin[J]. Med Mycol, 2005, 43(l1): 299-305.
[26]
Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1[J]. Antimicrob Agents Chemother, 2006, 50(6): 2058-2063.
[27]
Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates[J]. Antimicrob Agents Chemother, 2005, 49(8): 3264-3273.